Zymeworks Inc., a global biotech company, has released a corporate presentation highlighting its advancements in targeted therapies for challenging diseases such as aggressive cancers and complex autoimmune disorders. The presentation details Zymeworks' focus on developing best-in-class multifunctional therapeutics, including the development of next-generation antibody-drug conjugates and multispecific antibody therapeutics. Key programs such as ZW191, ZW220, and ZW251 in solid tumor oncology are discussed, along with collaborations with partners like Jazz Pharmaceuticals and BeOne. The presentation also mentions Ziihera®, which has been approved for second-line HER2-positive biliary tract cancer. You can access the full presentation through the link below.